AVDL
Avadel Pharmaceuticals plc (AVDL) SWOT Analysis Analysis (2026)
Overall Score
Strengths
AVDL has a strong liquidity position with a current ratio of 2.76 and cash ratio of 1.28.
Gross margin is very high at 95.5%, indicating strong product economics.
The company carries low leverage, with debt-to-equity at 0.38 and net debt-to-EBITDA at -3.62.
Free cash flow conversion is strong, with free cash flow nearly matching operating cash flow (FCF/OCF ratio of 0.99).
Weaknesses
Profitability remains thin, with net margin at 2.4% and operating margin at 4.0%.
Valuation is demanding, with EV/sales at 10.5x and price-to-free-cash-flow at 77.1x.
Interest coverage is only 1.12x, suggesting limited cushion if earnings weaken.
Working-capital efficiency is poor, reflected in a cash conversion cycle of 540 days.
Opportunities
If AVDL can sustain its high gross margin while scaling revenue, operating leverage could improve earnings.
The balance sheet provides room for investment in commercialization or pipeline development without immediate financing pressure.
Strong cash generation relative to capex leaves flexibility to fund growth initiatives internally.
Threats
The stock already prices in substantial growth, so any execution miss could pressure the valuation.
Low interest coverage leaves the company more exposed to earnings volatility or higher financing costs.
Extremely long inventory and payables cycles indicate operational inefficiency and potential working-capital strain.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Avadel Pharmaceuticals plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

